Insulin leader's first oral hypoglycemic drug will be approved to target 1.4 billion varieties

Medical Network News, August 17 Recently, Tonghua Dongbao Pharmaceutical's 4 generic listing applications for Sitagliptin phosphate tablets have entered the "under review" status, which is expected to usher in good news
.
Tonghua Dongbao Pharmaceutical focuses on insulin and its similar drugs in the diabetes field, and this product is expected to become the company's first approved oral hypoglycemic drug
.
Figure 1: Tonghua Dongbao Pharmaceutical's Sitagliptin Phosphate Tablets Registration Progress Source: NMPA's official website.
According to the data from Minai.
com, in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) ) In the market of terminal insulin and similar drugs, Tonghua Dongbao once won the domestic leading throne from 2013 to 2018, and was overtaken by Ganli Pharmaceutical from 2019
.
Table 1: Tonghua Dongbao's oral hypoglycemic drugs under review Source: Meinenet MED2.
0 Chinese Drug Evaluation Database In order to expand the diabetes treatment market, Tonghua Dongbao has increased its R&D investment in the field of oral hypoglycemic drugs in recent years
.
The company has submitted four generic listing applications for Repaglinide tablets, sitagliptin-metformin tablets (II) and sitagliptin phosphate tablets, among which sitagliptin phosphate tablets are expected to become the first approved product
.
Figure 2: Sales of sitagliptin phosphate tablets (unit: 10,000 yuan) Source: Mynet.
com China's public medical institutions' terminal competition pattern.
Sitagliptin phosphate tablets are a potent and highly selective dipeptidyl peptidase -4 (DPP-4) inhibitor, a new type of oral antihyperglycemic drug based on incretin mechanism, used to improve blood sugar control in patients with type 2 diabetes
.
After the product entered the National Medical Insurance Catalog in 2017, sales soared, and domestic generic drugs were approved in 2020.
At present, the market is still led by the original research drug company Merck
.
Table 2: sitagliptin phosphate tablets listing application Source: rice network MED2.
0 Chinese Drug Evaluation database current domestic generic terms, there are five companiesApproved and deemed to have been reviewed.
In addition, there are 8 companies under review.
It can be foreseen that the competition in the domestic market for sitagliptin phosphate tablets will intensify
.
Source: NMPA official website, Minet.
com database.
The review data statistics are as of August 13.
If there are any errors or omissions, please correct me
.